Development and Validation of the Oral Mucositis Risk Assessment Scale in Hematology Patients

Fidan, Özlem; Arslan, Sümeyye

doi:10.1016/j.soncn.2021.151159

Cited by 10 publications

(3 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Stool culture results for Clostridium difficile and Norovirus were recorded for patients who experienced diarrhoea, if available. Oral and oropharyngeal mucositis was assessed as G0 (none), G1 (mild), G2 (moderate), G3 (severe) or G4 (life‐threatening), according to the WHO mucositis toxicity scale 24 . Constipation was graded based upon the following criteria: complaint for up to 3 days (mild); more than 3 days requiring laxative use (moderate); and persisting more than 3 days with no response to first‐line laxatives (severe).…”

Section: Methodsmentioning

confidence: 99%

“…Oral and oropharyngeal mucositis was assessed as G0 (none), G1 (mild), G2 (moderate), G3 (severe) or G4 (life-threatening), according to the WHO mucositis toxicity scale. 24 Constipation was graded based upon the following criteria: complaint for up to 3 days (mild); more than 3 days requiring laxative use (moderate); and persisting more than 3 days with no response to firstline laxatives (severe). Dysphagia was simply classified as either present or absent.…”

Section: Nismentioning

confidence: 99%

See 1 more Smart Citation

The nutritional impact of CD19‐targeted CAR‐T therapy versus BEAM chemotherapy for adult patients with lymphoma

Ahern,

Pham,

Sanderson

et al. 2023

J Human Nutrition Diet

View full text Add to dashboard Cite

BackgroundChimeric antigen receptor T (CAR‐T) cell therapy is a novel therapy demonstrating durable remissions in patients with refractory or relapsing non‐Hodgkin's B‐cell lymphoma. Maintaining a patient's nutritional status has been demonstrated to improve outcomes in cancer treatment. However, no studies have investigated how CAR‐T therapy affects nutritional status, nor compared its impact with other cancer treatments for this patient group. The primary aim of the present study was to investigate the effect of CAR‐T therapy on the prevalence of nutrition impact symptoms (NIS) and nutritional status within 30 days post‐treatment of patients with lymphoma compared to a conditioning regimen for autologous haematopoetic stem cell transplant (carmustine/BCNU, Etoposide, cytarabine/Ara‐C, Melphalan [BEAM] auto‐haematopoetic stem cell transplant [HSCT]).MethodsClinical notes of patients with lymphoma who underwent either CAR‐T therapy or BEAM auto‐HSCT between 2018 and 2021 were reviewed. Data extracted included body weight measurements and NIS, including decreased appetite, nausea, vomiting, diarrhoea, constipation, mucositis, cytokine release syndrome (CRS) and neurotoxicity at baseline and 30 ± 7 days post‐treatment.ResultsIn total, 129 adults with lymphoma (n = 88 CAR‐T vs. n = 41 BEAM) were included. Nutritional status was assessed in both groups at baseline prior to treatment. Mean absolute weight change was significantly different between groups (3.05 kg in CAR‐T, −5.9 kg in BEAM, p ≤ 0.001). This was also significant when weight loss was categorised into percentage weight loss (p = 0.01). CAR‐T patients experienced a significantly lower prevalence of decreased appetite (52.3% vs. 97.6%) nausea (25% vs. 78%,) vomiting (10.2% vs. 53.7%), diarrhoea (43.2% vs. 96.7%) and mucositis (5.7% vs. 75.6%) combined across all levels of severity compared to BEAM chemotherapy (all p ≤ 0.01). CRS and neurotoxicity, which are specific side effects of CAR‐T therapy, were moderately positively associated with weight loss.ConclusionsWeight loss, percentage weight loss and NIS were significantly reduced in CAR‐T compared to BEAM treatment. However, patients who experienced neurotoxicity during treatment did have significant weight loss.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Nismentioning

confidence: 99%

The nutritional impact of CD19‐targeted CAR‐T therapy versus BEAM chemotherapy for adult patients with lymphoma

Ahern,

Pham,

Sanderson

et al. 2023

J Human Nutrition Diet

View full text Add to dashboard Cite

show abstract

“…A mucosa oral é uma área facilmente afetada devido à sua frequente renovação das células (2). Portanto, a mucosite oral (MO) é uma das complicações dolorosas mais comuns da terapia oncológica, quase todos os pacientes que recebem esses tratamentos a desenvolvem(3).…”

Section: Introductionunclassified

Avaliação dos fatores preditivos que podem influenciar na dor por mucosite oral em pacientes oncológicos

Huayhua

View full text Add to dashboard Cite

Supportive Care

Linden

Harinck

Speksnijder

et al. 2023

The European Blood and Marrow Transplantation Textbook for Nurses

View full text Add to dashboard Cite

Hematopoietic stem cell transplantation (HSCT) care is highly complex. This chapter focuses on the aspects of supportive care required following HSCT.Assessment tools are key component of nursing practice and are necessary for planning and providing patient-centered care. HSCT care must be planned, implemented, and evaluated and is underpinned by collaboration with the entire multidisciplinary healthcare team.With supportive care following HSCT, we ultimately aim to improve the quality of life of our patients in the posttransplant period.Supportive care extends beyond symptom management and includes social, psychological, and spiritual care. The needs of the patient are multifactorial and can be complex, considering multiple issues at the same time and involving multiple disciplines.Throughout supportive nursing care, our clinical competence is critical and is complemented by experience, knowledge, and awareness.

show abstract

Development and Validation of the Oral Mucositis Risk Assessment Scale in Hematology Patients

Cited by 10 publications

References 42 publications

The nutritional impact of CD19‐targeted CAR‐T therapy versus BEAM chemotherapy for adult patients with lymphoma

The nutritional impact of CD19‐targeted CAR‐T therapy versus BEAM chemotherapy for adult patients with lymphoma

Avaliação dos fatores preditivos que podem influenciar na dor por mucosite oral em pacientes oncológicos

Supportive Care

Contact Info

Product

Resources

About